메뉴 건너뛰기




Volumn 7, Issue 7, 2007, Pages 1027-1041

New approaches in systemic treatment of advanced colorectal cancer: The molecular targets era

Author keywords

Colorectal cancer; EGF receptor; Monoclonal antibodies; Targeted therapy; Tyrosine kinase ihibitors; VEGF

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; K RAS PROTEIN; LACTATE DEHYDROGENASE; MATUZUMAB; OXALIPLATIN; PANITUMUMAB; PELITINIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; THROMBOSPONDIN 2; UNCLASSIFIED DRUG; VASCULOTROPIN; VATALANIB; ZD 1829;

EID: 34547503209     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.7.1027     Document Type: Review
Times cited : (5)

References (91)
  • 1
    • 34547538375 scopus 로고    scopus 로고
    • Ries LAG, Harkins D, Krapcho M et al. SEER Cancer Statistic Review, 1975-2003. National Cancer Institute, MD, USA (2006).
    • Ries LAG, Harkins D, Krapcho M et al. SEER Cancer Statistic Review, 1975-2003. National Cancer Institute, MD, USA (2006).
  • 2
    • 0027379619 scopus 로고
    • The chemotherapy of colon cancer can no longer be ignored
    • Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur. J. Cancer 29A, 2077-2079(1993).
    • (1993) Eur. J. Cancer , vol.29 A , pp. 2077-2079
    • Cunningham, D.1    Findlay, M.2
  • 3
    • 0033616484 scopus 로고    scopus 로고
    • Colorectal cancer
    • Midgley R, Kerr D. Colorectal cancer. Lancet 353(9150), 391-399 (1999).
    • (1999) Lancet , vol.353 , Issue.9150 , pp. 391-399
    • Midgley, R.1    Kerr, D.2
  • 4
    • 0034596549 scopus 로고    scopus 로고
    • Palliative chemotherapy for advanced colorectal cancer: Systematic review and mcta-analysis. Colorectal Collaborative Group
    • Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and mcta-analysis. Colorectal Collaborative Group. Br. Med. J. 321(7260), 531-535 (2000).
    • (2000) Br. Med. J , vol.321 , Issue.7260 , pp. 531-535
    • Simmonds, P.C.1
  • 5
    • 0024513402 scopus 로고    scopus 로고
    • O'Connell MJ. A Phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 63, S1026-S1030 (1989).
    • O'Connell MJ. A Phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 63, S1026-S1030 (1989).
  • 6
    • 0024385167 scopus 로고
    • The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomised Phase III trial. Gastrointestinal Tumor Study Group
    • Petrelli N, Douglas HO Jr, Herrera L et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomised Phase III trial. Gastrointestinal Tumor Study Group. J. Clin. Oncol. 7(10), 1419-1426 (1989).
    • (1989) J. Clin. Oncol , vol.7 , Issue.10 , pp. 1419-1426
    • Petrelli, N.1    Douglas Jr, H.O.2    Herrera, L.3
  • 7
    • 4644252335 scopus 로고    scopus 로고
    • Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis
    • The Meta-Analysis Group in Cancer
    • The Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol. 22, 3766-3775 (2004).
    • (2004) J. Clin. Oncol , vol.22 , pp. 3766-3775
  • 8
    • 0034727063 scopus 로고    scopus 로고
    • Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group
    • Saltz L, Cox fV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343(13), 905-914 (2000).
    • (2000) N. Engl. J. Med , vol.343 , Issue.13 , pp. 905-914
    • Saltz, L.1    fV, C.2    Blanke, C.3
  • 9
    • 0033874892 scopus 로고    scopus 로고
    • Leucovorin and flourouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    • De Gramont A, Figer A, Seymour M et al. Leucovorin and flourouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18(6), 2938-2947 (2000).
    • (2000) J. Clin. Oncol , vol.18 , Issue.6 , pp. 2938-2947
    • De Gramont, A.1    Figer, A.2    Seymour, M.3
  • 10
    • 0034712536 scopus 로고    scopus 로고
    • Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
    • Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 25, 1041-1047 (2000).
    • (2000) Lancet , vol.25 , pp. 1041-1047
    • Douillard, J.Y.1    Cunningham, D.2    Roth, A.D.3
  • 11
    • 33644843853 scopus 로고    scopus 로고
    • OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study
    • Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J. Clin. Oncol. 24, 394-400 (2006).
    • (2006) J. Clin. Oncol , vol.24 , pp. 394-400
    • Tournigand, C.1    Cervantes, A.2    Figer, A.3
  • 12
    • 1342290189 scopus 로고    scopus 로고
    • FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
    • Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22, 229-237 (2004).
    • (2004) J. Clin. Oncol , vol.22 , pp. 229-237
    • Tournigand, C.1    Andre, T.2    Achille, E.3
  • 13
    • 33750851725 scopus 로고    scopus 로고
    • The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs. the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer: Results of a randomized Phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.)
    • Abstract 3513
    • Falcone A, Masi G, Brunetti G et al. The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs. the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer: results of a randomized Phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.). Proc. Am. Soc. Clin. Oncol. 24, S18 (2006) (Abstract 3513).
    • (2006) Proc. Am. Soc. Clin. Oncol , vol.24
    • Falcone, A.1    Masi, G.2    Brunetti, G.3
  • 14
    • 1642468240 scopus 로고    scopus 로고
    • Long term survivors of metastatic colorectal cancer treated with chemotherapy only: A North Central Cancer Treatment Group review
    • Abstract 693
    • Hobday TJ, Cha SS, Sargent DJ et al. Long term survivors of metastatic colorectal cancer treated with chemotherapy only: a North Central Cancer Treatment Group review. Proc. Am. Soc. Clin. Oncol. 21, (2002) (Abstract 693).
    • (2002) Proc. Am. Soc. Clin. Oncol , vol.21
    • Hobday, T.J.1    Cha, S.S.2    Sargent, D.J.3
  • 15
    • 85013312416 scopus 로고
    • Tumor angiogenesis: Therapeutic implications
    • Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182-1186 (1971).
    • (1971) N. Engl. J. Med , vol.285 , Issue.21 , pp. 1182-1186
    • Folkman, J.1
  • 16
    • 0037699954 scopus 로고    scopus 로고
    • The biology of VEGF and its receptors
    • Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9(6), 669-676 (2003).
    • (2003) Nat. Med , vol.9 , Issue.6 , pp. 669-676
    • Ferrara, N.1    Gerber, H.P.2    LeCouter, J.3
  • 17
    • 0037967272 scopus 로고    scopus 로고
    • Tumorigenesis and the angiogenic switch
    • Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401-410 (2003).
    • (2003) Nat. Rev. Cancer , vol.3 , pp. 401-410
    • Bergers, G.1    Benjamin, L.E.2
  • 18
    • 0027197245 scopus 로고
    • Inhibition of vascular endothelial growth factor induced angiogenesis suppresses turnout growth in vivo
    • Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses turnout growth in vivo. Nature 362(6423), 841-844 (1993).
    • (1993) Nature , vol.362 , Issue.6423 , pp. 841-844
    • Kim, K.J.1    Li, B.2    Winer, J.3
  • 20
    • 0034075041 scopus 로고    scopus 로고
    • Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients
    • Lee JC, Chow NH, Wang ST Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur. J. Cancer 36(6), 748-753 (2000).
    • (2000) Eur. J. Cancer , vol.36 , Issue.6 , pp. 748-753
    • Lee, J.C.1    Chow, N.H.2    Wang ST Huang, S.M.3
  • 21
    • 0028935608 scopus 로고
    • Regulation by vascular endothetial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis
    • Warren RS, Yuan H, Madi MR, Gillett NA, Ferrara N. Regulation by vascular endothetial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95(4), 1789-1797 (1995).
    • (1995) J. Clin. Invest , vol.95 , Issue.4 , pp. 1789-1797
    • Warren, R.S.1    Yuan, H.2    Madi, M.R.3    Gillett, N.A.4    Ferrara, N.5
  • 22
    • 20044375603 scopus 로고    scopus 로고
    • Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
    • Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7(4), 335-345 (2004).
    • (2004) Angiogenesis , vol.7 , Issue.4 , pp. 335-345
    • Wang, Y.1    Fei, D.2    Vanderlaan, M.3    Song, A.4
  • 23
    • 0038235987 scopus 로고    scopus 로고
    • Effect of antivascular endothelial growth factor treatment on the intramural uptake of CPT-11
    • Wildiers H, Guetens G, De Boeck G et al. Effect of antivascular endothelial growth factor treatment on the intramural uptake of CPT-11. Br. J. Cancer 88 (12), 1979-1986 (2003).
    • (2003) Br. J. Cancer , vol.88 , Issue.12 , pp. 1979-1986
    • Wildiers, H.1    Guetens, G.2    De Boeck, G.3
  • 24
    • 11844254414 scopus 로고    scopus 로고
    • Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
    • Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005).
    • (2005) Science , vol.307 , pp. 58-62
    • Jain, R.K.1
  • 25
    • 0037208589 scopus 로고    scopus 로고
    • Phase II randomised trial comparing bevacizumab plus flourouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
    • Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II randomised trial comparing bevacizumab plus flourouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21(l), 60-65 (2003).
    • (2003) J. Clin. Oncol , vol.21 , Issue.L , pp. 60-65
    • Kabbinavar, F.1    Hurwitz, H.I.2    Fehrenbacher, L.3
  • 26
    • 20544478429 scopus 로고    scopus 로고
    • Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomised Phase II trial
    • Kabbinabar F, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomised Phase II trial. J. Clin. Oncol. 23(16), 3697-3705 (2005).
    • (2005) J. Clin. Oncol , vol.23 , Issue.16 , pp. 3697-3705
    • Kabbinabar, F.1    Schulz, J.2    McCleod, M.3
  • 27
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J Med. 350(23), 2335-2342 (2004).
    • (2004) N. Engl. J Med , vol.350 , Issue.23 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3
  • 28
    • 21244481589 scopus 로고    scopus 로고
    • High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200
    • Abstract 2
    • Giantonio BJ, Catalano PJ, Meropol NJ et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc. Am. Soc. Clin. Oncol. 23, 16S (2005) (Abstract 2).
    • (2005) Proc. Am. Soc. Clin. Oncol , vol.23
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3
  • 29
    • 34249293549 scopus 로고    scopus 로고
    • Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/ NO16966, a randomized Phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC)
    • Presented at:, Orlando, FL, USA, 19-21 January, Abstract 238
    • Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/ NO16966, a randomized Phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA, 19-21 January 2007 (Abstract 238).
    • (2007) American Society of Clinical Oncology Gastrointestinal Cancers Symposium
    • Saltz, L.B.1    Clarke, S.2    Diaz-Rubio, E.3
  • 30
    • 33749016960 scopus 로고    scopus 로고
    • Safety and efficacy of oxaliplatin/fluoropyirimidine regimens with or without bevacizumab as first-line treatment of metastacic colorectal cancer: Final analysis of the TREE-study
    • Abstract 3510
    • Hochster HS, Hart LL, Ramanathan RK, Hainsworth JD, Hedrick FE, Childs BH. Safety and efficacy of oxaliplatin/fluoropyirimidine regimens with or without bevacizumab as first-line treatment of metastacic colorectal cancer: final analysis of the TREE-study. Proc. Am. Soc. Clin. Oncol. 24, 18S (2006) (Abstract 3510).
    • (2006) Proc. Am. Soc. Clin. Oncol , vol.24
    • Hochster, H.S.1    Hart, L.L.2    Ramanathan, R.K.3    Hainsworth, J.D.4    Hedrick, F.E.5    Childs, B.H.6
  • 31
    • 22744445443 scopus 로고    scopus 로고
    • Safety and efficacy of bevacizumab when added to oxaliplatin/fuoropyrimidine regimens as first-line treatment of colorectal cancer: TREE 1 & 2 Studies
    • Abstract 3515
    • Hochster HS, Welles L, Hart L et al. Safety and efficacy of bevacizumab when added to oxaliplatin/fuoropyrimidine regimens as first-line treatment of colorectal cancer: TREE 1 & 2 Studies. Proc. Am. Soc. Clin. Oncol. 23, 16S (2005) (Abstract 3515).
    • (2005) Proc. Am. Soc. Clin. Oncol , vol.23
    • Hochster, H.S.1    Welles, L.2    Hart, L.3
  • 32
    • 33748999448 scopus 로고    scopus 로고
    • Safety of bevacizumab plus chemotherapy as first-line treatment of patient with metastasic colorectal cancer: Update results from a large observational registry in the US (BRiTE)
    • Abstract 3536
    • Hedrick E, Kozloff M, Hainsworth J et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patient with metastasic colorectal cancer: update results from a large observational registry in the US (BRiTE). Proc. Am. Soc. Clin. Oncol. 24, 18S (2006) (Abstract 3536).
    • (2006) Proc. Am. Soc. Clin. Oncol , vol.24
    • Hedrick, E.1    Kozloff, M.2    Hainsworth, J.3
  • 33
    • 33749585632 scopus 로고    scopus 로고
    • Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI and capecitabine for metastatic colorectal cancer: First B.E.A. Trial
    • Abstract 3534
    • Berry SR, Cunningham D, Michael M et al. Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI and capecitabine for metastatic colorectal cancer: first B.E.A. Trial. Proc. Am. Soc. Clin. Oncol. 24, 18S (2006) (Abstract 3534).
    • (2006) Proc. Am. Soc. Clin. Oncol , vol.24
    • Berry, S.R.1    Cunningham, D.2    Michael, M.3
  • 34
    • 33750154101 scopus 로고    scopus 로고
    • Feasibility of metastasectomy in patients treated with bevacizumab in first-line metastatic colorectal cancer: Preliminary results from the First Beat study
    • Abstract 3523
    • Michael M, Van Cutsem E, Kretzschmar A et al. Feasibility of metastasectomy in patients treated with bevacizumab in first-line metastatic colorectal cancer: preliminary results from the First Beat study. Proc. Am. Soc. Clin. Oncol. 24, 18S (2006) (Abstract 3523).
    • (2006) Proc. Am. Soc. Clin. Oncol , vol.24
    • Michael, M.1    Van Cutsem, E.2    Kretzschmar, A.3
  • 35
    • 34547508055 scopus 로고    scopus 로고
    • Feasibility of metastasectomy in patients treated with first-line bevacizumab for mCRC: Preliminary results from the First BEAT study
    • Presented at:, Orlando, FL, USA, 19-21 January, Abstract 343
    • Kretzschmar A, Cunningham D, Berry S et al. Feasibility of metastasectomy in patients treated with first-line bevacizumab for mCRC: preliminary results from the First BEAT study. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA, 19-21 January 2007 (Abstract 343).
    • (2007) American Society of Clinical Oncology Gastrointestinal Cancers Symposium
    • Kretzschmar, A.1    Cunningham, D.2    Berry, S.3
  • 36
    • 34547494400 scopus 로고    scopus 로고
    • Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab for colorectal cancer (CRC) liver metastases
    • Presented at:, Orlando, FL, USA, 19-21 January, Abstract 234
    • Kesmodel SB, Ellis LM, Lin E et al. Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab for colorectal cancer (CRC) liver metastases. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA, 19-21 January 2007 (Abstract 234).
    • (2007) American Society of Clinical Oncology Gastrointestinal Cancers Symposium
    • Kesmodel, S.B.1    Ellis, L.M.2    Lin, E.3
  • 37
    • 33746833739 scopus 로고    scopus 로고
    • Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: An NCI Treatment Referral Center Trial TRC-0301
    • Chen HX, Mooney M, Boron M et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J. Clin. Oncol. 24(21), 3354-3360 (2006).
    • (2006) J. Clin. Oncol , vol.24 , Issue.21 , pp. 3354-3360
    • Chen, H.X.1    Mooney, M.2    Boron, M.3
  • 38
    • 33644823334 scopus 로고    scopus 로고
    • Impact of vascular endothelial growth factor-A expression, thrombosporin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer
    • Jubb AM, Hurwitz HL, Bai W et al. Impact of vascular endothelial growth factor-A expression, thrombosporin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol. 24, 217-227 (2006).
    • (2006) J. Clin. Oncol , vol.24 , pp. 217-227
    • Jubb, A.M.1    Hurwitz, H.L.2    Bai, W.3
  • 39
    • 33846478656 scopus 로고    scopus 로고
    • DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
    • O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br. J. Cancer 96(2), 189-195 (2007).
    • (2007) Br. J. Cancer , vol.96 , Issue.2 , pp. 189-195
    • O'Connor, J.P.1    Jackson, A.2    Parker, G.J.3    Jayson, G.C.4
  • 40
    • 7444222477 scopus 로고    scopus 로고
    • Phase I/II study of PTK787/ZK222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer
    • Abstract 3558
    • Schleucher N, Trarbach T, Junker U et al. Phase I/II study of PTK787/ZK222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 22, S14 (2004) (Abstract 3558).
    • (2004) Proc. Am. Soc. Clin. Oncol , vol.22
    • Schleucher, N.1    Trarbach, T.2    Junker, U.3
  • 41
    • 33947157250 scopus 로고    scopus 로고
    • A Phase lb, open label, parallel design study of PTK787/ZK 222584 in combination with irinotecan in patients with metastatic colorectal cancer to investigate the interaction between the agents
    • Abstract 3594
    • Tejpar S, Lin E, Bono P et al. A Phase lb, open label, parallel design study of PTK787/ZK 222584 in combination with irinotecan in patients with metastatic colorectal cancer to investigate the interaction between the agents. Proc. Am. Soc. Clin. Oncol. 23, 16S (2005) (Abstract 3594).
    • (2005) Proc. Am. Soc. Clin. Oncol , vol.23
    • Tejpar, S.1    Lin, E.2    Bono, P.3
  • 42
    • 23844548194 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled, Phase III study in patients with metastatic adenocarcinoma ofthe colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM 1)
    • Abstract 3
    • Hecht JR, Trarbach T, Jaeger E et al. A randomized, double-blind, placebo-controlled, Phase III study in patients with metastatic adenocarcinoma ofthe colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM 1). Proc. Am. Soc. Clin. Oncol. 23, 16S (2005) (Abstract 3).
    • (2005) Proc. Am. Soc. Clin. Oncol , vol.23
    • Hecht, J.R.1    Trarbach, T.2    Jaeger, E.3
  • 43
    • 33749637207 scopus 로고    scopus 로고
    • Results of an interim analysis of a multinational randomised, double blind, Phase III study in patients with previously treated metastatic colorectal cancer receiving FOLOFOX4 and PTK787/ZK222584 (PTK/ZK) or placebo (CONFIRM 2)
    • Abstract 3508
    • Koehne C, Bajetta E, Lin E et al. Results of an interim analysis of a multinational randomised, double blind, Phase III study in patients with previously treated metastatic colorectal cancer receiving FOLOFOX4 and PTK787/ZK222584 (PTK/ZK) or placebo (CONFIRM 2). Proc. Am. Soc. Clin. Oncol. 24, 18S (2006) (Abstract 3508).
    • (2006) Proc. Am. Soc. Clin. Oncol , vol.24
    • Koehne, C.1    Bajetta, E.2    Lin, E.3
  • 44
    • 33846352097 scopus 로고    scopus 로고
    • A meta-analyisis of two randomised, double-blind, placebo-controlled, Phase III studies in patients with matastatic colorectal cancer receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival in high LDH patients
    • Abstract 3529
    • Major P, Trarbach T, Lenz H et al. A meta-analyisis of two randomised, double-blind, placebo-controlled, Phase III studies in patients with matastatic colorectal cancer receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival in high LDH patients. Proc. Am. Soc. Clin. Oncol. 24, 18S (2006) (Abstract 3529).
    • (2006) Proc. Am. Soc. Clin. Oncol , vol.24
    • Major, P.1    Trarbach, T.2    Lenz, H.3
  • 45
    • 20144370978 scopus 로고    scopus 로고
    • AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer
    • Wedge SR, Kendrew J, Hennequin LF et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65(10), 4389-4400 (2005).
    • (2005) Cancer Res , vol.65 , Issue.10 , pp. 4389-4400
    • Wedge, S.R.1    Kendrew, J.2    Hennequin, L.F.3
  • 46
    • 0026471016 scopus 로고
    • Prognostic markers of colorectal cancer: An evaluation of DNA content, epidermal growth factor receptor, and Ki-67
    • Hemming AW, Davis NL, Kluffinger A et al. Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J. Surg. Oncol. 51(3), 147-152 (1992).
    • (1992) J. Surg. Oncol , vol.51 , Issue.3 , pp. 147-152
    • Hemming, A.W.1    Davis, N.L.2    Kluffinger, A.3
  • 47
    • 0036500831 scopus 로고    scopus 로고
    • Monoclonal antibodies to target epidermal growth factor receptor positive tumors: A new paradigm for cancer therapy
    • Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor positive tumors: a new paradigm for cancer therapy. Cancer 94(5), 1593-1611 (2002).
    • (2002) Cancer , vol.94 , Issue.5 , pp. 1593-1611
    • Herbst, R.S.1    Shin, D.M.2
  • 48
    • 0028819660 scopus 로고
    • Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
    • Goldstein NI, Prewett M, Zuklys K, Rockwell P. Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1(11), 1311-1318 (1995).
    • (1995) Clin. Cancer Res , vol.1 , Issue.11 , pp. 1311-1318
    • Goldstein, N.I.1    Prewett, M.2    Zuklys, K.3    Rockwell, P.4    Mendelsohn, J.5
  • 49
    • 0002823211 scopus 로고    scopus 로고
    • Cctuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory coloeectal canccr that express the epidermal growth factor receptor
    • Abstract 7
    • Saltz LB, Rubin M, Hochster H et al. Cctuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory coloeectal canccr that express the epidermal growth factor receptor. Proc. Am. Soc. Clin. Oncol. 20, 3A (2001) (Abstract 7).
    • (2001) Proc. Am. Soc. Clin. Oncol , vol.20
    • Saltz, L.B.1    Rubin, M.2    Hochster, H.3
  • 50
    • 2142641698 scopus 로고    scopus 로고
    • Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor
    • Saltz LB, Meropol NJ, Lochrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J. Clin. Oncol. 22(7), 1201-1208 (2004).
    • (2004) J. Clin. Oncol , vol.22 , Issue.7 , pp. 1201-1208
    • Saltz, L.B.1    Meropol, N.J.2    Lochrer Sr, P.J.3    Needle, M.N.4    Kopit, J.5    Mayer, R.J.6
  • 51
    • 3242720345 scopus 로고    scopus 로고
    • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    • Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004).
    • (2004) N. Engl. J. Med , vol.351 , Issue.4 , pp. 337-345
    • Cunningham, D.1    Humblet, Y.2    Siena, S.3
  • 52
    • 34547542923 scopus 로고    scopus 로고
    • MABEL - a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan
    • Abstract 3549
    • Wilke H, Glynne-Jones R, Thaler J et al. MABEL - a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan. Proc. Am. Soc. Clin. Oncol. 24, S18 (2006) (Abstract 3549).
    • (2006) Proc. Am. Soc. Clin. Oncol , vol.24
    • Wilke, H.1    Glynne-Jones, R.2    Thaler, J.3
  • 53
    • 33750615769 scopus 로고    scopus 로고
    • Multicenter Phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    • Lenz HJ, Van Cursern E, Khambata-Ford S et al. Multicenter Phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J. Clin. Oncol. 24(30), 4914-4921 (2006).
    • (2006) J. Clin. Oncol , vol.24 , Issue.30 , pp. 4914-4921
    • Lenz, H.J.1    Van Cursern, E.2    Khambata-Ford, S.3
  • 54
    • 0001407137 scopus 로고    scopus 로고
    • Erbitux (IMC-C225) plus weekly irinotecan, fluorouracil, and leucovorin in colorectal cancer that express the epidermal growth factor receptor
    • Abstract 536
    • Rosenberg AH, Loebrer PJ, Needle MN et al. Erbitux (IMC-C225) plus weekly irinotecan, fluorouracil, and leucovorin in colorectal cancer that express the epidermal growth factor receptor. Proc. Am. Soc. Clin. Oncol. 21(2002) (Abstract 536).
    • (2002) Proc. Am. Soc. Clin. Oncol , vol.21
    • Rosenberg, A.H.1    Loebrer, P.J.2    Needle, M.N.3
  • 56
    • 16244372110 scopus 로고    scopus 로고
    • Cetuximab plus FOLFIRI as first-line treatment for metastatic colorectal cancer
    • Abstract 3513
    • Rougier P, Raoul J-L, Van Laethem J-L et al. Cetuximab plus FOLFIRI as first-line treatment for metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 22, 14S (2004) (Abstract 3513).
    • (2004) Proc. Am. Soc. Clin. Oncol , vol.22
    • Rougier, P.1    Raoul, J.-L.2    Van Laethem, J.-L.3
  • 57
    • 34547495706 scopus 로고    scopus 로고
    • Cervantes A, Tabernero J, Van Cutsem E et al. An international Phase II study of cetuximab in combination with oxaliplatin/ 5-fluorouracil/folinic acid (FOLFOX4) in the first-line treatment of patients with metastatic colorectal cancer expressing epidermal growth factor receptor (EGFR). Presented at: 13th European Conference on Clinical Oncology and 24th Annual Meeting of the European Society for Therapeutic Radiology and Oncology. Lieu, Paris, France, 30 October-3 November 2005 (Abstract 642).
    • Cervantes A, Tabernero J, Van Cutsem E et al. An international Phase II study of cetuximab in combination with oxaliplatin/ 5-fluorouracil/folinic acid (FOLFOX4) in the first-line treatment of patients with metastatic colorectal cancer expressing epidermal growth factor receptor (EGFR). Presented at: 13th European Conference on Clinical Oncology and 24th Annual Meeting of the European Society for Therapeutic Radiology and Oncology. Lieu, Paris, France, 30 October-3 November 2005 (Abstract 642).
  • 58
    • 27644491153 scopus 로고    scopus 로고
    • Phase I/II study of cetuximab combined with 5-fluorouracil/ leucovorin plus weekly oxaliplatin in first-line treatment of epidermal growth factor receptor-cxpressing metastatic colorectal cancer
    • Presented at:, Vienna, Austria, 29 October-2 November
    • Hohler T. Phase I/II study of cetuximab combined with 5-fluorouracil/ leucovorin plus weekly oxaliplatin in first-line treatment of epidermal growth factor receptor-cxpressing metastatic colorectal cancer. Presented at: 30th European Society of Medical Oncology Congress. Vienna, Austria, 29 October-2 November 2004.
    • (2004) 30th European Society of Medical Oncology Congress
    • Hohler, T.1
  • 59
    • 33749038520 scopus 로고    scopus 로고
    • The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorcctal cancer: A randomised Phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)
    • Abstract 3551
    • Borner M, Mingrone W, Koeberle D et al. The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorcctal cancer: a randomised Phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). Proc. Am. Soc. Clin. Oncol. 24, 18S (2006) (Abstract 3551).
    • (2006) Proc. Am. Soc. Clin. Oncol , vol.24
    • Borner, M.1    Mingrone, W.2    Koeberle, D.3
  • 60
    • 45249117578 scopus 로고    scopus 로고
    • FOLFOX4 + cetuximab in untreated patients with advanced colorectal cancer. A Phase II study of the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2402)
    • Abstract 3559
    • Cotucci G, Giuliani F, Mattioli R et al. FOLFOX4 + cetuximab in untreated patients with advanced colorectal cancer. A Phase II study of the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2402). Proc. Am. Soc. Clin. Oncol. 24, S18 (2006) (Abstract 3559).
    • (2006) Proc. Am. Soc. Clin. Oncol , vol.24
    • Cotucci, G.1    Giuliani, F.2    Mattioli, R.3
  • 61
    • 33750905700 scopus 로고    scopus 로고
    • Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) +/- cetuximab for patients with untreated metastatic colorectal adenocarcinoma of the colon or rectum: CALGB 80203 preliminary results
    • Abstract 3509
    • Venook A, Niedzwiecki D, Hollis D et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) +/- cetuximab for patients with untreated metastatic colorectal adenocarcinoma of the colon or rectum: CALGB 80203 preliminary results. Proc. Am. Soc. Clin. Oncol. 24, 18S (2006) (Abstract 3509).
    • (2006) Proc. Am. Soc. Clin. Oncol , vol.24
    • Venook, A.1    Niedzwiecki, D.2    Hollis, D.3
  • 63
    • 33750017775 scopus 로고    scopus 로고
    • Optimal dose of cetuximab given every two weeks: A Phase I pharmacokinetic and pharmacodynamic study of weekly and every two weeks schedules in patients with metastatic colorectal cancer
    • Abstract 3085
    • Tabernero, J, Cervantes A, Martinelli E et al. Optimal dose of cetuximab given every two weeks: a Phase I pharmacokinetic and pharmacodynamic study of weekly and every two weeks schedules in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 24, 18S (2006) (Abstract 3085).
    • (2006) Proc. Am. Soc. Clin. Oncol , vol.24
    • Tabernero, J.1    Cervantes, A.2    Martinelli, E.3
  • 64
    • 23844454976 scopus 로고    scopus 로고
    • Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer
    • Abstract 3520
    • Malik I, Hecht JR, Patnaik A et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 23, S16 (2005) (Abstract 3520).
    • (2005) Proc. Am. Soc. Clin. Oncol , vol.23
    • Malik, I.1    Hecht, J.R.2    Patnaik, A.3
  • 65
    • 33846474852 scopus 로고    scopus 로고
    • Panitumumab significantly improves progression free survival in patients with metastatic colorectal cancer
    • Presented at:, Barcelona, Spain, 28 June-2 July
    • van Cutsem E, Peeters M, Siena S et al. Panitumumab significantly improves progression free survival in patients with metastatic colorectal cancer. Presented at: 8th World Congress on Gastrointestinal Cancer. Barcelona, Spain, 28 June-2 July 2006.
    • (2006) 8th World Congress on Gastrointestinal Cancer
    • van Cutsem, E.1    Peeters, M.2    Siena, S.3
  • 66
    • 1542344622 scopus 로고    scopus 로고
    • Phase I study ofthe humanized anti-epidermal growth factor receptor monoclonal antibody EDM-72000 in patients with advanced solid tumors that express the epidermal growth factor receptor
    • Vanhoefer U, Tewes M, Rojo F et al. Phase I study ofthe humanized anti-epidermal growth factor receptor monoclonal antibody EDM-72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin. Oncol. 22(1), 175-184 (2004).
    • (2004) J Clin. Oncol , vol.22 , Issue.1 , pp. 175-184
    • Vanhoefer, U.1    Tewes, M.2    Rojo, F.3
  • 67
    • 20144366145 scopus 로고    scopus 로고
    • A Phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer
    • Mackenzie MJ, Hirte HW, Glenwood G et al. A Phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest. New Drugs 23(2), 165-170 (2005).
    • (2005) Invest. New Drugs , vol.23 , Issue.2 , pp. 165-170
    • Mackenzie, M.J.1    Hirte, H.W.2    Glenwood, G.3
  • 68
    • 33644822287 scopus 로고    scopus 로고
    • Randomized Phase II trial of the clinical and biological effect of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma
    • Rothenberg ML, LaFleur B, Levy DE et al. Randomized Phase II trial of the clinical and biological effect of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J. Clin. Oncol. 23(36), 9265-9274 (2005).
    • (2005) J. Clin. Oncol , vol.23 , Issue.36 , pp. 9265-9274
    • Rothenberg, M.L.1    LaFleur, B.2    Levy, D.E.3
  • 69
    • 6444230253 scopus 로고    scopus 로고
    • A Phase II study of gefitinib in combination with FOLFOX4 in patients with metastatic colorectal cancer
    • Abstract 3514
    • Fisher GA, Kun T, Cho CD et al. A Phase II study of gefitinib in combination with FOLFOX4 in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 22, 14S (2004) (Abstract 3514).
    • (2004) Proc. Am. Soc. Clin. Oncol , vol.22
    • Fisher, G.A.1    Kun, T.2    Cho, C.D.3
  • 70
    • 23244446134 scopus 로고    scopus 로고
    • Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer
    • Kindler HL, Friberg G, Skoog L, Wade-Oliver K, Vokes E. Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. Am. J. Clin. Oncol., 28(4), 340-344 (2005).
    • (2005) Am. J. Clin. Oncol , vol.28 , Issue.4 , pp. 340-344
    • Kindler, H.L.1    Friberg, G.2    Skoog, L.3    Wade-Oliver, K.4    Vokes, E.5
  • 71
    • 33750155908 scopus 로고    scopus 로고
    • Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer
    • Wolpin BM, Clark JW, Meyerhardt JA et al. Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. Clin. Colorectal Cancer 6(3), 208-213 (2006).
    • (2006) Clin. Colorectal Cancer , vol.6 , Issue.3 , pp. 208-213
    • Wolpin, B.M.1    Clark, J.W.2    Meyerhardt, J.A.3
  • 72
    • 20344380924 scopus 로고    scopus 로고
    • A Phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer
    • Veronesse ML, Sun W, Giantonio B et al. A Phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Br. J. Cancer 92(10), 1846-1849 (2005).
    • (2005) Br. J. Cancer , vol.92 , Issue.10 , pp. 1846-1849
    • Veronesse, M.L.1    Sun, W.2    Giantonio, B.3
  • 73
    • 24944484717 scopus 로고    scopus 로고
    • Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer
    • Kuo T, Cho CD, Halsey J et al. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J. Clin. Oncol. 23(24), 5613-5619 (2005).
    • (2005) J. Clin. Oncol , vol.23 , Issue.24 , pp. 5613-5619
    • Kuo, T.1    Cho, C.D.2    Halsey, J.3
  • 74
    • 33646143020 scopus 로고    scopus 로고
    • Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
    • Townsley CA, Major P, Sin LL et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br. J. Cancer 94(8), 1136-1143 (2006).
    • (2006) Br. J. Cancer , vol.94 , Issue.8 , pp. 1136-1143
    • Townsley, C.A.1    Major, P.2    Sin, L.L.3
  • 75
    • 31444447068 scopus 로고    scopus 로고
    • Ertotinib as 2nd and 3rd hne monotherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohorts Phase II trial
    • Abstract 3575
    • Keilholz U, Arnold D, Niederle N et al. Ertotinib as 2nd and 3rd hne monotherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohorts Phase II trial. Proc. Am. Soc. Clin. Oncol.. 23, S16 (2005) (Abstract 3575).
    • (2005) Proc. Am. Soc. Clin. Oncol , vol.23
    • Keilholz, U.1    Arnold, D.2    Niederle, N.3
  • 76
    • 4444315825 scopus 로고    scopus 로고
    • Erlotinib HCI in combination with FOLFOX-4 in patients with advanced solid tumors
    • Abstract 789
    • Hanauske AR, Diaz-Rubio E, Cassidy J et al. Erlotinib HCI in combination with FOLFOX-4 in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 22 (2003) (Abstract 789).
    • (2003) Proc. Am. Soc. Clin. Oncol , vol.22
    • Hanauske, A.R.1    Diaz-Rubio, E.2    Cassidy, J.3
  • 77
    • 33646361363 scopus 로고    scopus 로고
    • Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated pitients with metastatic colorectal cancer
    • Meyerhardt JA, Zhu AX, Enzinger PC et al. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated pitients with metastatic colorectal cancer. J. Clin. Oncol. 24(12), 1892-1897 (2006).
    • (2006) J. Clin. Oncol , vol.24 , Issue.12 , pp. 1892-1897
    • Meyerhardt, J.A.1    Zhu, A.X.2    Enzinger, P.C.3
  • 78
    • 33044483743 scopus 로고    scopus 로고
    • A Phase lb dose-escalation trial of ertotinib, capecitabine, and oxaliplatin in metastatic colorectal cancer patients
    • Abstract 3585
    • Delord JP, Beale P, Van Cutsem E et al. A Phase lb dose-escalation trial of ertotinib, capecitabine, and oxaliplatin in metastatic colorectal cancer patients. Proc. Am. Soc. Clin. Oncol. 22, S14 (2004) (Abstract 3585).
    • (2004) Proc. Am. Soc. Clin. Oncol , vol.22
    • Delord, J.P.1    Beale, P.2    Van Cutsem, E.3
  • 79
    • 34547510680 scopus 로고    scopus 로고
    • Phase II study of FOLFOX4, bevacizumab, and erlotinib as first-line therapy in patients with advanced colorectal cancer
    • Presented at:, San Francisco, CA, USA, 26-28 January, Abstract 238
    • Spigel DR, Hainsworth JD, Burris HA et al. Phase II study of FOLFOX4, bevacizumab, and erlotinib as first-line therapy in patients with advanced colorectal cancer. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 26-28 January 2006 (Abstract 238).
    • (2006) American Society of Clinical Oncology Gastrointestinal Cancers Symposium
    • Spigel, D.R.1    Hainsworth, J.D.2    Burris, H.A.3
  • 80
    • 33749602434 scopus 로고    scopus 로고
    • Phase II study of FOLFOX, bevacizumab and erlotinib as initial therapy for patients with metastatic colorectal cancer
    • Abstract 3545
    • Meyerhardt JA, Stuart K, Zhu A et al. Phase II study of FOLFOX, bevacizumab and erlotinib as initial therapy for patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 24, S18 (2006) (Abstract 3545).
    • (2006) Proc. Am. Soc. Clin. Oncol , vol.24
    • Meyerhardt, J.A.1    Stuart, K.2    Zhu, A.3
  • 81
    • 22744445568 scopus 로고    scopus 로고
    • Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4), in patients with advanced colorectal cancer
    • Abstract 3579
    • Tejpar S, Van Cutsem E, Gamelin D et al. Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4), in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 22, 14S (2004) (Abstract 3579).
    • (2004) Proc. Am. Soc. Clin. Oncol , vol.22
    • Tejpar, S.1    Van Cutsem, E.2    Gamelin, D.3
  • 82
    • 22744447033 scopus 로고    scopus 로고
    • A Phase I/IIA pharmacokinetic and serial skin and tumor pharmacodynamic study of the EGFR irreversible tyrosine kinase inhibitor EKB-569, in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI regimen) in patients with advanced colorectal cancer
    • Abstract 3543
    • Casado E, Folprecht G, Paz-Ares L et al. A Phase I/IIA pharmacokinetic and serial skin and tumor pharmacodynamic study of the EGFR irreversible tyrosine kinase inhibitor EKB-569, in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI regimen) in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 22, S14 (2004) (Abstract 3543).
    • (2004) Proc. Am. Soc. Clin. Oncol , vol.22
    • Casado, E.1    Folprecht, G.2    Paz-Ares, L.3
  • 83
    • 33749237209 scopus 로고    scopus 로고
    • A Phase I pharmacokinetic and molecular pharmacodynamic of the combination of two auti-EGFR therapies, the monoclonal antibody cetuximab, and the tyrosine kinase inhibitior gefitimb, in patients with advanced colorectal, head and neck, and non-small cell lung cancer
    • Abstract 3006
    • Baselga J, Schöffski P, Rojo F et al. A Phase I pharmacokinetic and molecular pharmacodynamic of the combination of two auti-EGFR therapies, the monoclonal antibody cetuximab, and the tyrosine kinase inhibitior gefitimb, in patients with advanced colorectal, head and neck, and non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol.. 24, S18 (2006) (Abstract 3006).
    • (2006) Proc. Am. Soc. Clin. Oncol , vol.24
    • Baselga, J.1    Schöffski, P.2    Rojo, F.3
  • 84
    • 0344773402 scopus 로고    scopus 로고
    • The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignances
    • Abstract 817
    • Saltz I., Kies M, Abbruzzese JL et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignances. Proc. Am. Soc. Clin. Oncol.. 22, (2003) (Abstract 817).
    • (2003) Proc. Am. Soc. Clin. Oncol , vol.22
    • Saltz, I.1    Kies, M.2    Abbruzzese, J.L.3
  • 85
    • 34547174846 scopus 로고    scopus 로고
    • Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic and efficacy data of a randomized study
    • Presented at:, Orlando, FL, USA, 19-21 January, Abstract 237
    • Van Cutsem E, Humbler Y, Gelderblom H et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic and efficacy data of a randomized study. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL, USA, 19-21 January 2007 (Abstract 237).
    • (2007) American Society of Clinical Oncology Gastrointestinal Cancers Symposium
    • Van Cutsem, E.1    Humbler, Y.2    Gelderblom, H.3
  • 86
    • 33748146468 scopus 로고    scopus 로고
    • Lack of usefulness of epidermal growth factor receptor determination for cetuximab therapy in patients with colorectal cancer
    • Hebbar N, Wacranier A, Desauw C et al. Lack of usefulness of epidermal growth factor receptor determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 17(7), 855-857 (2006).
    • (2006) Anticancer Drugs , vol.17 , Issue.7 , pp. 855-857
    • Hebbar, N.1    Wacranier, A.2    Desauw, C.3
  • 87
    • 20144381957 scopus 로고    scopus 로고
    • Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
    • Chung KI, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol.. 23(9), 1803-1810 (2005).
    • (2005) J. Clin. Oncol , vol.23 , Issue.9 , pp. 1803-1810
    • Chung, K.I.1    Shia, J.2    Kemeny, N.E.3
  • 88
    • 17844362179 scopus 로고    scopus 로고
    • Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: A cohort study
    • Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6(5), 257-258 (2005).
    • (2005) Lancet Oncol , vol.6 , Issue.5 , pp. 257-258
    • Moroni, M.1    Veronese, S.2    Benvenuti, S.3
  • 89
    • 33646228635 scopus 로고    scopus 로고
    • KRAS mutations status is predictive of response to cetuximab therapy in colorectal cancer
    • Lievre A, Bachet JB, Le Corte D et al. KRAS mutations status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66(8), 3992-3995 (2006).
    • (2006) Cancer Res , vol.66 , Issue.8 , pp. 3992-3995
    • Lievre, A.1    Bachet, J.B.2    Le Corte, D.3
  • 90
    • 0033818695 scopus 로고    scopus 로고
    • Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells
    • Ciardello F, Bianco R, Damiano V et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res. 6, 3739-3747 (2000).
    • (2000) Clin. Cancer Res , vol.6 , pp. 3739-3747
    • Ciardello, F.1    Bianco, R.2    Damiano, V.3
  • 91
    • 21244475037 scopus 로고    scopus 로고
    • Randomised Phase II study of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
    • Abstract 3508
    • Saltz LB, Lenz H, Hochster S et al. Randomised Phase II study of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol. 23, S16 (2005) (Abstract 3508).
    • (2005) Proc. Am. Soc. Clin. Oncol , vol.23
    • Saltz, L.B.1    Lenz, H.2    Hochster, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.